Search | OpenScholar

Search results

356 results found

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.

Publication: Journal Article

Hauser, RA, R Pahwa, WA Wargin, CJ Souza-Prien, N McClure, R Johnson, JT Nguyen, R Patni, and GT Went. 2018. “Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet 2019;58:77-88.”. Clin Pharmacokinet.

Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 2016;33:127-133.

Publication: Journal Article

Wills, AA, JJ Elm, R Ye, KL Chou, SA Parashos, RA Hauser, I Bodis-Wollner, et al. 2016. “Cognitive Function in 1736 Participants in NINDS Exploratory Trials in PD Long-Term Study-1. Parkinsonism Relat Disord 2016;33:127-133.”. Parkinsonism Relat Disord.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.

Publication: Journal Article

Hauser, RA, MF Gordon, Y Mizuno, W Poewe, P Barone, AH Schapira, O Rascol, C Debieuvre, and M Fradorf. 2014. “Minimal Clinically Important Difference in Parkinson’s Disease As Assessed in Pivotal Trials of Pramipexole Extended Release. Parkinsons Dis. 2014; Parkinsons Dis 2014;2014:467131.”. Parkinsons Dis.

Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29:1171-80.

Publication: Journal Article

Goldman, SM, F Kamel, GW Ross, SA Jewell, C Marras, JA Hoppin, DM Umbach, et al. 2014. “Peptidoglycan Recognition Protein Genes and Risk of Parkinson’s Disease. Mov Disord 2014;29:1171-80.”. Mov Disord.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13:767-76.

Publication: Journal Article

Hauser, RA, CW Olanow, KD Kieburtz, E Pourcher, A Docu-Axelerad, M Lew, O Kozyolkin, et al. 2014. “Tozadenant (SYN115) in Patients With Parkinson’s Disease Who Have Motor Fluctuations on Levodopa: A Phase 2b, Double-Blind, Randomised Trial. Lancet Neurol 2014;13:767-76.”. Lancet Neurol.

Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.

Publication: Journal Article

Bajaj, N, RA Hauser, J Seibyl, A Kupsch, M Plotkin, C Chen, and ID Grachev. 2014. “Association Between Hoehn and Yahr, Mini-Mental State Examination, Age, and Clinical Syndrome Predominance and Diagnostic Effectiveness of Ioflupane I 123 Injection (DaTSCAN™) in Subjects With Clinically Uncertain Parkinsonian Syndromes.”. Alzheimers Res Ther.

Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-6.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, RA Hauser, JM Miyasaki, AP Nicholas, W Poewe, et al. 2013. “Which Dyskinesia Scale Best Detects Treatment Response? Mov Disord 2013;28:341-6.”. Mov Disord.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017;89:1959-1969.

Publication: Journal Article

Mollenhauer, B, CJ Caspell-Garcia, CS Coffey, P Taylor, LM Shaw, JQ Trojanowski, A Singleton, et al. 2017. “Longitudinal CSF Biomarkers in Patients With Early Parkinson Disease and Healthy Controls. Neurology 2017;89:1959-1969.”. Neurology.

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-56.

Publication: Journal Article

Hauser, RA, A Hsu, S Kell, AJ Espay, K Sethi, M Stacy, W Ondo, M O’Connell, and S Gupta. 2013. “Extended-Release Carbidopa-Levodopa (IPX066) Compared With Immediate-Release Carbidopa-Levodopa in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 3 Randomised, Double-Blind Trial. Lancet Neurol 2013;12:346-56.”. Lancet Neurol.

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18:370-6.

Publication: Journal Article

Rascol, O, J Bronzova, RA Hauser, AE Lang, C Sampaio, A Theeuwes, and SV Van De Witte. 2012. “Pardoprunox As Adjunct Therapy to Levodopa in Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Results of a Double-Blind, Randomized, Placebo-Controlled, Trial. Parkinsonism Relat Disord 2012;18:370-6.”. Parkinsonism Relat Disord.